Exact Sciences Corporation

NasdaqCM:EXAS 株式レポート

時価総額:US$9.4b

Exact Sciences マネジメント

マネジメント 基準チェック /24

Exact Sciencesの CEO はKevin Conroyで、 Apr2009年に任命され、 の在任期間は 15.58年です。 の年間総報酬は$ 16.12Mで、 6.5%給与と93.5%のボーナス(会社の株式とオプションを含む)で構成されています。 は、会社の株式の0.38%を直接所有しており、その価値は$ 36.25M 。経営陣と取締役会の平均在任期間はそれぞれ3.8年と5.7年です。

主要情報

Kevin Conroy

最高経営責任者

US$16.1m

報酬総額

CEO給与比率6.5%
CEO在任期間15.6yrs
CEOの所有権0.4%
経営陣の平均在職期間3.8yrs
取締役会の平均在任期間5.7yrs

経営陣の近況

Recent updates

Why Investors Shouldn't Be Surprised By Exact Sciences Corporation's (NASDAQ:EXAS) 27% Share Price Plunge

Nov 10
Why Investors Shouldn't Be Surprised By Exact Sciences Corporation's (NASDAQ:EXAS) 27% Share Price Plunge

We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt

Sep 25
We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt

Exact Sciences: Cost Optimization And Product Strength

Aug 18

Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Aug 14
Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Exact Sciences: Still No Reason To Own

Jun 11

Revenues Working Against Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Following 27% Dive

Jun 02
Revenues Working Against Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Following 27% Dive

An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 46% Undervalued

Feb 23
An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 46% Undervalued

Investors Don't See Light At End Of Exact Sciences Corporation's (NASDAQ:EXAS) Tunnel

Jan 08
Investors Don't See Light At End Of Exact Sciences Corporation's (NASDAQ:EXAS) Tunnel

Exact Sciences Corporation (NASDAQ:EXAS) Shares Could Be 42% Below Their Intrinsic Value Estimate

Nov 15
Exact Sciences Corporation (NASDAQ:EXAS) Shares Could Be 42% Below Their Intrinsic Value Estimate

Exact Sciences (NASDAQ:EXAS) Is Carrying A Fair Bit Of Debt

Oct 04
Exact Sciences (NASDAQ:EXAS) Is Carrying A Fair Bit Of Debt

An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 44% Undervalued

Aug 14
An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 44% Undervalued

Here's Why Exact Sciences (NASDAQ:EXAS) Can Afford Some Debt

Jun 15
Here's Why Exact Sciences (NASDAQ:EXAS) Can Afford Some Debt

Calculating The Fair Value Of Exact Sciences Corporation (NASDAQ:EXAS)

Apr 26
Calculating The Fair Value Of Exact Sciences Corporation (NASDAQ:EXAS)

We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt

Feb 23
We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt

CEO報酬分析

Exact Sciences の収益と比較して、Kevin Conroy の報酬はどのように変化したか?
日付総報酬給与会社業績
Sep 30 2024n/an/a

-US$214m

Jun 30 2024n/an/a

-US$175m

Mar 31 2024n/an/a

-US$240m

Dec 31 2023US$16mUS$1m

-US$204m

Sep 30 2023n/an/a

-US$282m

Jun 30 2023n/an/a

-US$432m

Mar 31 2023n/an/a

-US$517m

Dec 31 2022US$14mUS$510k

-US$624m

Sep 30 2022n/an/a

-US$716m

Jun 30 2022n/an/a

-US$735m

Mar 31 2022n/an/a

-US$745m

Dec 31 2021US$15mUS$963k

-US$596m

Sep 30 2021n/an/a

-US$793m

Jun 30 2021n/an/a

-US$829m

Mar 31 2021n/an/a

-US$720m

Dec 31 2020US$20mUS$499k

-US$824m

Sep 30 2020n/an/a

-US$327m

Jun 30 2020n/an/a

-US$165m

Mar 31 2020n/an/a

-US$136m

Dec 31 2019US$19mUS$792k

-US$213m

Sep 30 2019n/an/a

-US$216m

Jun 30 2019n/an/a

-US$221m

Mar 31 2019n/an/a

-US$219m

Dec 31 2018US$7mUS$696k

-US$175m

Sep 30 2018n/an/a

-US$143m

Jun 30 2018n/an/a

-US$124m

Mar 31 2018n/an/a

-US$119m

Dec 31 2017US$13mUS$633k

-US$114m

報酬と市場: Kevinの 総報酬 ($USD 16.12M ) は、 US市場 ($USD 7.84M ) の同規模の企業の平均を上回っています。

報酬と収益: Kevinの報酬は増加しましたが、会社は利益を上げていません。


CEO(最高経営責任者

Kevin Conroy (58 yo)

15.6yrs

在職期間

US$16,119,899

報酬

Mr. Kevin T. Conroy served as Independent Director of SomaLogic, Inc. since September 1, 2021, until January 2022. Mr. Conroy had served as an Independent Director of Adaptive Biotechnologies Corporation s...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Kevin Conroy
Chairman of The Board & CEO15.6yrsUS$16.12m0.38%
$ 36.2m
Jake Orville
Executive VP & GM of Screeningno dataUS$3.67m0.0084%
$ 792.7k
Brian Baranick
Executive VP & General Manager of Precision Oncologyno dataUS$3.57m0.0071%
$ 673.0k
Aaron Bloomer
Executive Vice President of Financeless than a yearデータなしデータなし
Jorge Garces
Chief Science Officer3.6yrsデータなしデータなし
Nassar Nizami
Chief Information Officer1.8yrsデータなしデータなし
Megan Jones
Associate Manager of Investor Relationsno dataデータなしデータなし
Tim Caprez
Chief Compliance Counsel & VP9.8yrsデータなしデータなし
James Herriott
Senior VP2.8yrsデータなし0.0060%
$ 562.7k
Sarah Condella
Executive Vice President of Human Resources7.5yrsUS$2.71m0.042%
$ 4.0m
Graham Lidgard
Emeritus Chief Science Officer3.8yrsUS$4.21mデータなし
Ana Hooker
Chief Laboratory Officer9.3yrsUS$3.95mデータなし

3.8yrs

平均在職期間

50yo

平均年齢

経験豊富な経営陣: EXASの経営陣は 経験豊富 であると考えられます ( 3.8年の平均在職年数)。


取締役

名称ポジション在職期間報酬所有権
Kevin Conroy
Chairman of The Board & CEO15.7yrsUS$16.12m0.38%
$ 36.2m
Daniel Levangie
Independent Director14.3yrsUS$408.75k0.015%
$ 1.4m
D. Coward
Director1.9yrsUS$1.47m0.030%
$ 2.8m
Katherine Zanotti
Independent Director15.6yrsUS$406.25k0.038%
$ 3.6m
Michael Barber
Independent Directorless than a yearデータなし0.0029%
$ 277.1k
Paul Clancy
Independent Director3.7yrsUS$417.75k0.011%
$ 1.0m
Kathleen Sebelius
Independent Director5.7yrsUS$411.75k0.017%
$ 1.6m
Shacey Petrovic
Independent Director4.3yrsUS$401.25k0.012%
$ 1.2m
James Doyle
Lead Independent Director10.3yrsUS$442.75k0.030%
$ 2.8m

5.7yrs

平均在職期間

63yo

平均年齢

経験豊富なボード: EXASの 取締役会経験豊富 であると考えられます ( 5.7年の平均在任期間)。